Dyne Therapeutics (DYN) Equity Average (2019 - 2026)

Dyne Therapeutics' Equity Average history runs 8 years deep, the most recent figure standing at $918.6 million for Q1 2026.

• In Q1 2026, Equity Average rose 41.45% year-over-year to $918.6 million; the TTM figure through Mar 2026 stood at $918.6 million (up 41.45% YoY), while the FY2025 annual figure was $801.0 million, up 122.15% from the prior year.
• Equity Average was $918.6 million for Q1 2026 at Dyne Therapeutics, up from $832.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $918.6 million in Q1 2026 to a low of $121.7 million in Q4 2023.
• Historically, Equity Average has averaged $466.3 million across 5 years, with a median of $352.3 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Equity Average tumbled 51.54% in 2023, then soared 448.79% in 2024.
• A 5-year view of Equity Average shows it stood at $251.1 million in 2022, then sank by 51.54% to $121.7 million in 2023, then jumped by 448.79% to $667.7 million in 2024, then rose by 24.6% to $832.0 million in 2025, then rose by 10.41% to $918.6 million in 2026.
• The last three Equity Average figures came in at $918.6 million (Q1 2026), $832.0 million (Q4 2025), and $631.6 million (Q3 2025), per Business Quant data.